

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board
SBI Holdings, Inc.
Yoshitaka Kitao
Chief Executive Officer

Japan, 16 April 2012

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Kenji Hirai, Mr Tomoya Asakura, Mr Takashi Okita, Mr Noriaki Maruyama, Mr Shumpei Morita, Mr Shinji Yamauchi, Mr Makoto Miyazaki, Mr Yoshimi Takahashi and Mr Masaki Takayanagi, the non-executive Directors are Mr Yasutaro Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura and Mr Hiroshi Tasaka and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Takeshi Natsuno and Mr Akihiro Tamaki.

April 16, 2012

SBI Holdings, Inc.

(TOKYO: 8473 / Hong Kong: 6488)

Notice on Agreement with Bahrain Government
for the Promotion of the 5-ALA Business

It is hereby notified that SBI Pharmaceuticals Co., Ltd., the SBI Holdings, Inc. subsidiary engaged in the research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA) (*1) (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereafter called “SBI Pharmaceuticals”) reached a basic agreement and concluded a memorandum of understanding with the Bahrain Government for promoting the research and development of 5-ALA and its penetration in Bahrain and GCC (*2) through close cooperation between both parties.

From now on, SBI Pharmaceuticals will continue to explore the potential of a wide range of 5-ALA’s clinical applications, starting with a joint clinical trial with Bahrain Defence Force Royal Medical Services Military Hospital (headquartered in Riffa), a Bahraini public hospital. SBI Pharmaceuticals identifies Bahrain as its drug research and development base in the Middle East and North Africa (MENA), and will also look at the option of expanding its business operations into the neighboring countries.

SBI Pharmaceuticals will continue to make utmost efforts in performing research and development of 5-ALA-based drugs with the aim of serving to protect the health of as many people as possible not only in Japan, but also around the world.

*1 About 5-aminolevulinic acid (5-ALA):

An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

*2 About GCC (Gulf Cooperation Council) :

An abbreviation for the Cooperation Council for the Arab states of the Gulf, the Middle East and Arabian Gulf regional cooperation organization, which includes Bahrain.

For further information, please contact:

SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126

SBI Pharmaceuticals Co., Ltd.: Corporate Development Dept., Tel: +81 3 6229 0095